iRhythm plunges after Q3 miss, Zio MCT delay

 

iRhythm beats Q3 2026 EPS estimates with $0.82 (+612% YoY), misses revenue, raises 2026 guidance as Zio AT growth stalls

• Full-year 2026 revenue and adjusted EBITDA margin guidance hike driven largely by acquired VitalConnect revenue, implying weaker organic growth.
• Planned Zio MCT launch pushed back, with management now targeting only an FDA submission in 2027.
• Q3 2026 revenue rose 14.9% year over year to $221.6M, below revenue estimates.

https://finviz.com/stock?t=IRTC&p=d